Physician profile
Abaid Ullah Choudry
NPI 1235246588
$708.91
in general payments reported to CMS, 2019-2025
13 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2022: $29.14 · 2023: $41.14 · 2024: $127 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $237.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $91.72 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $88.27 | 2025 | |
| Mannkind Corporation | $57.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.21 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $42.19 | 2019-2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $31.22 | 2024-2025 | Gvoke Hypopen |
| Insulet Corporation | $28.36 | 2025 | Omnipod |
| Dexcom, INC. | $22.86 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $15.56 | 2025 | Voquezna |
| Abbvie INC. | $15.24 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.64 | 2022 | |
| Athena Bioscience, LLC | $10.28 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abaid Choudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.